Results 151 to 160 of about 24,512 (278)
ABSTRACT ABCB4 translocates phospholipids (PL) into bile to buffer the toxicity of bile acids (BA) and free cholesterol (CHOL). While recessively inherited ABCB4 deficiency causes childhood Progressive Familial Intrahepatic Cholestasis type 3, haploinsufficiency has been linked to adult‐onset hepatobiliary diseases.
Eric L. Bell +6 more
wiley +1 more source
ABSTRACT Background and Aims Pruritus is a debilitating, under‐prioritized symptom of primary biliary cholangitis (PBC). This study assessed its impact on healthcare resource utilization (HCRU) and costs in the US. Methods A retrospective cohort study of individuals with PBC was conducted using Komodo's claims and laboratory data between September 1 ...
Robert G. Gish +8 more
wiley +1 more source
Transcription factors SOX4 and SOX9 cooperatively control development of intrahepatic bile ducts
In developing liver, cholangiocytes derive from the hepatoblasts and organize to form the bile ducts. Earlier work has shown that SOX9 is transiently required for bile duct development, raising the question of the potential involvement of other SOX ...
Poncy, Alexis
core
Encephalopathy: Cause, Pathogenesis, and Treatment
Various encephalopathies (sepsis‐associated, hepatic, hypoxic–ischemic, diabetic, uremic, toxic) have incompletely elucidated pathogenesis, which severely restricts targeted therapy development. Small molecule drugs show unique multitarget potential but face toxicity, poor blood–brain barrier penetration and unclear specificity.
Shimeng Lv +7 more
wiley +1 more source
Intrahepatic cholestasis in chronic liver disease
Cholestasis syndromes are characterized by a reflux of compounds usually excreted with bile. ATP dependent carriers and cytoskeleton proteins guarantee physiological bile flux.
Pezzoli A. +7 more
core
Imaging diagnosis of Caroli-like disease with concurrent extrahepatic biliary obstruction in a young small-breed dog: case report. [PDF]
Park J, Cho SY, Kiupel M, Lee K, Yoon H.
europepmc +1 more source
This phase II study explored the efficacy and safety of HAIC plus toripalimab in locally advanced HCC. The primary endpoint was the PFS rate at 6 months. The 6‐month PFS rate was 63.9% in the TorHAIC group and 61.1% in the SoraHAIC group. Treatment with the TorHAIC regimen resulted in a median OS of 20.9 months and a median PFS of 9.1 months.
Zhicheng Lai +12 more
wiley +1 more source
Spectrum of Biliary and Nonbiliary Neoplasms Growing and Spreading Within the Lumen of the Bile Ducts. [PDF]
Nakanuma Y, Sato Y, Kakuda Y, Oishi T.
europepmc +1 more source
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu +6 more
wiley +1 more source
Case Report: Primary squamous cell carcinoma of the pancreatic segment of the extrahepatic bile duct: a rare tumor easily misdiagnosed as pancreatic malignancy. [PDF]
Xu T +5 more
europepmc +1 more source

